Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
Home Headlines J&J pulls COVID vaccine sales forecast due to low demand, supply glut
Headlines

J&J pulls COVID vaccine sales forecast due to low demand, supply glut

by jcp April 19, 2022
April 19, 2022
gawdo

By Manas Mishra and Michael Erman

(Reuters) -Johnson & Johnson on Tuesday rescinded its forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world.

The company had previously predicted as much as $3.5 billion in 2022 sales from the single-dose vaccine, but demand has withered.

Still, the company reported strong results for its medical devices business and raised its dividend, driving shares up around 3%.

Use of the shot has been weak in high-income countries, hurt by reports of rare, potentially deadly blood clots, production issues, including an accidental mix-up of ingredients by a contract manufacturer, and concerns about efficacy.

J&J’s COVID vaccine accounts for about 3% of all doses administered in the United States, and roughly 2% of doses in Europe.

Because of the soft demand from Europe and the United States, much of the company’s supply has been shipped to lower income countries. As a one-shot vaccine that can be refrigerated for months, many hoped uptake would be better, but executives said it has encountered the same vaccine hesitancy as other manufacturers.

“Governments want to act, and what they’re seeing is their populations are just a little bit more reticent than what we see in the U.S. or the G5 with respect to accepting a vaccine,” J&J Chief Financial Officer Joseph Wolk said in an interview.

Wolk noted that infrastructure, including refrigeration, has also been a hurdle for getting shots in arms in developing countries.

The World Health Organization has said poorer countries have asked for insufficient doses to meet its goal of vaccinating at least 70% of their populations by the middle of the year.

The vaccine, which is sold at a not-for-profit price, brought in $457 million in the first quarter. J&J recorded vaccine sales of $2.39 billion last year.

Pfizer Inc has forecast $32 billion in 2022 sales from its COVID vaccine developed with BioNTech SE, while Moderna Inc has forecast $21 billion for its shot this year.

J&J also cut both ends of its full-year profit forecast by 25 cents and now expects to earn $10.15 to $10.35 per share. But it blamed the move on currency fluctuations rather than fundamental business issues and raised its dividend 6.6%.

“With the guidance cut driven exclusively by currency, I think shares are reacting to the forward looking comments,” said Edward Jones analyst Ashtyn Evans. “J&J discussed accelerating growth in medical technology through acquisitions and also the belief that supply chain issues will improve in the second half of the year.”

Other analysts said J&J remains a safe bet within the healthcare sector and that raising the dividend provided predictable income for investors despite vaccine sales woes.

J&J said its medical devices unit should recover this year after pandemic delays in non-urgent surgeries, and it expects above-market growth in its large pharmaceuticals business in 2022, despite falling short of Wall Street estimates in the first quarter.

The company reported pharmaceutical sales of $12.87 billion, well shy of forecasts for $13.6 billion, due in part to low vaccine sales.

Excluding items, J&J earned $2.67 per share for the quarter, beating analysts’ expectations by 11 cents, according to Refinitiv.

(Reporting by Manas Mishra in Bengaluru, additional reporting by Michael Erman in New Jersey; Editing by Arun Koyyur and Bill Berkrot)

www.gawdo.com
Share on FacebookShare on TwitterShare on Linkedin
0 FacebookTwitterPinterestEmail
previous post
Biden, Johnson, Trudeau pledge artillery for Ukraine in battle against Russia
next post
Diamond miner De Beers returns to Angola after ten-year absence

You may also like

Finland, Sweden to send teams to Turkey to...

May 24, 2022

Germany’s vaccine panel says one COVID shot enough...

May 24, 2022

EU calls for Russia dialogue to unlock Ukraine...

May 24, 2022
Editorial & Advertiser disclosureEditorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gawdo.com
https://www.gawdo.com
  • About us
  • Advertising & Terms of Use
  • Contact Us
  • Privacy Policy

@2021 - All Right Reserved.


Back To Top
Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT